Get in touch with one of our Xperts.
Inez de Greef elected as fellow of the Netherlands Academy of Engineering We are thrilled to announce that Inez de Greef, CEO of Treeway and co-founder and Managing Partner of 3D-PharmXchange, has been elected as a fellow of the Netherlands Academy of Engineering (NAE). The NAE brings together top experts in technological sciences and applied continue reading…
A successful drug development strategy is a well-designed and dynamic process. Making sure regulatory requirements are embedded from the start, is key. From pre-clinical all the way to registration, a well-organized set of action plans needs to be in place that guides and accelerates the client’s vision on how to support their targeted therapeutic area. continue reading…
3D-PharmXchange will be attending, exhibiting and/or presenting at the following conferences and events in 2023: Click on the event name for more information. Event Date(s) Location Exhibitor/Attendee World ADC March 13-16 London Attendee Bioprocessing Summit Europe March 14-16 Barcelona Attendee Dutch ATMP Summit March 15 Amsterdam Attendee DIA Europe March 22-24 Basel Attendee Innovation for continue reading…
The proof-of-concept studies have shown promising results and bring a therapy a step closer to the clinic. But what is needed before this therapy can show its efficacy in a clinical trial? Cell therapy is a promising treatment, but its development is challenging due to its complex technology and the regulatory framework in which it continue reading…
In 2013, Inez de Greef – van der Sandt was appointed as CEO for our client Treeway, a biotechnology company with a mission to develop therapies to cure ALS. Treeway is a clinical-stage biotechnology company with a mission to develop therapies to cure ALS. It was founded in 2012 by two ALS patients, Bernard Muller continue reading…
The Göttingen Minipig was developed at the University in Göttingen, Germany to meet the demand for a non-rodent model with many similarities to humans as genetic management is required to minimise inbreeding and drift and to maintain the genetic integrity of the population. The genetics for the entire breeding population is still managed in Göttingen continue reading…
The valley of death is often mentioned when talking about drug development. It’s the place where most biotech companies do not survive. Not Treeway, a small Dutch biotech company that made it to the other side. A drug development strategy is a well-designed and dynamic process, which is performed by most companies in stages. From continue reading…
The 4 pivotal questions you have on PDEs answered: A shared concern on how to create science-based PDEs. From a safety perspective, all companies with multifunctional pharmaceutical and chemical production facilities must be able to adequately determine cleaning limits and permitted daily exposures (PDEs) by characterizing the effects of possible cross-contamination in the non-intended patient continue reading…
© 3D-PharmXchange 2025